Suppr超能文献

角膜移植排斥反应的管理——病例系列报告及文献综述

Management of Corneal Graft Rejection - A Case Series Report and Review of the Literature.

作者信息

Nguyen Pho, Barte Felise, Shinada Shuntaro, Yiu Samuel C

机构信息

Doheny Eye Institute and the Department of Ophthalmology, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.

出版信息

J Clin Exp Ophthalmol. 2010 Sep 29;1(103). doi: 10.4172/2155-9570.1000103.

Abstract

PURPOSE

To report long-term results in a case series of patients treated with systemic immune suppression for prevention of penetrating keratoplasty (PKP) graft rejection. DESIGN: Retrospective noncomparative chart review. PARTICIPANTS: Three patients presented with PKP graft failure. METHODS: Patients received oral prednisone, azathioprine and cyclosporine to prevent rejection of repeat corneal transplant. Patients received repeat PKP and graft outcome was reported. MAIN OUTCOME MEASURES: Visual acuity and graft survival were recorded. RESULTS: Mean age was 55 years, two male and one female. Mean follow-up period was 37 months (range 24-46). All three patients completed the treatment protocol with minimal adverse effects. All grafts remained clear over observational period. CONCLUSION: Our study suggests that systemic immune suppression with 2 or more agents may be helpful to prevent corneal graft rejection in high-risk patients.

摘要

目的

报告一系列接受全身免疫抑制治疗以预防穿透性角膜移植术(PKP)移植物排斥反应患者的长期结果。

设计

回顾性非对照图表审查。

参与者

三名出现PKP移植物失败的患者。

方法

患者接受口服泼尼松、硫唑嘌呤和环孢素以预防再次角膜移植的排斥反应。患者接受再次PKP并报告移植物结果。

主要观察指标

记录视力和移植物存活情况。

结果

平均年龄55岁,两名男性和一名女性。平均随访期为37个月(范围24 - 46个月)。所有三名患者均完成治疗方案,且不良反应最小。在观察期内所有移植物均保持透明。

结论

我们的研究表明,使用两种或更多药物进行全身免疫抑制可能有助于预防高危患者的角膜移植物排斥反应。

相似文献

1
Management of Corneal Graft Rejection - A Case Series Report and Review of the Literature.
J Clin Exp Ophthalmol. 2010 Sep 29;1(103). doi: 10.4172/2155-9570.1000103.
2
Immunosuppressants for the prophylaxis of corneal graft rejection after penetrating keratoplasty.
Cochrane Database Syst Rev. 2015 Aug 27;2015(8):CD007603. doi: 10.1002/14651858.CD007603.pub2.
4
Large-diameter penetrating keratoplasty: indications and outcomes.
Cornea. 2010 Mar;29(3):296-301. doi: 10.1097/ICO.0b013e3181b6489e.
5
Indications for and outcomes of penetrating keratoplasty performed by resident surgeons.
Am J Ophthalmol. 2003 Jul;136(1):68-75. doi: 10.1016/s0002-9394(02)02295-x.
7
Long-term outcomes of penetrating keratoplasty in chronic and delayed mustard gas keratitis.
Cornea. 2007 Oct;26(9):1074-8. doi: 10.1097/ICO.0b013e3181334752.
8
Treatment of fungal keratitis by penetrating keratoplasty.
Br J Ophthalmol. 2001 Sep;85(9):1070-4. doi: 10.1136/bjo.85.9.1070.
9
Twelve-year follow-up of penetrating keratoplasty.
Jpn J Ophthalmol. 2017 Mar;61(2):131-136. doi: 10.1007/s10384-016-0489-2. Epub 2016 Nov 24.
10
Penetrating keratoplasty for endothelial decompensation in eyes with buphthalmos.
Cornea. 2003 Apr;22(3):198-204. doi: 10.1097/00003226-200304000-00003.

引用本文的文献

1
Rejection of Acellular Porcine Corneal Stroma Transplantation During Coronavirus Disease 2019 Pandemic.
J Craniofac Surg. 2022;33(5):1300-1302. doi: 10.1097/SCS.0000000000008324. Epub 2021 Oct 27.
2
Thermal imaging of corneal transplant rejection.
Int Ophthalmol. 2018 Dec;38(6):2335-2339. doi: 10.1007/s10792-017-0731-z. Epub 2017 Nov 4.
3
Outcome of repeat penetrating keratoplasty in eyes with failed penetrating keratoplasty.
Saudi Med J. 2016 Sep;37(9):1029-32. doi: 10.15537/smj.2016.9.14075.
4
Ocular surface rehabilitation: Application of human amniotic membrane in high-risk penetrating keratoplasties.
Saudi J Ophthalmol. 2014 Jul;28(3):198-202. doi: 10.1016/j.sjopt.2014.06.010. Epub 2014 Jul 2.
5
Sclerokeratoplasty as the Therapy for Corneal Perforation due to Exposure and Neurotrophic Keratopathy.
Case Rep Ophthalmol Med. 2014;2014:467249. doi: 10.1155/2014/467249. Epub 2014 Jan 15.
8
Strategies for local gene therapy of corneal allograft rejection.
Middle East Afr J Ophthalmol. 2013 Jan-Mar;20(1):11-25. doi: 10.4103/0974-9233.106382.

本文引用的文献

1
Tacrolimus immunosuppression in high-risk corneal grafts.
Br J Ophthalmol. 2007 Jan;91(1):51-5. doi: 10.1136/bjo.2006.097428. Epub 2006 Sep 6.
2
Prevention and treatment of corneal graft rejection: current practice patterns (2004).
Cornea. 2006 Apr;25(3):286-90. doi: 10.1097/01.ico.0000178731.42187.46.
3
How effective is penetrating corneal transplantation? Factors influencing long-term outcome in multivariate analysis.
Transplantation. 2006 Mar 27;81(6):896-901. doi: 10.1097/01.tp.0000185197.37824.35.
4
Toxicity-sparing protocols using mycophenolate mofetil in renal transplantation.
Transplantation. 2005 Oct 15;80(2 Suppl):S221-34. doi: 10.1097/01.tp.0000186386.13597.cb.
5
Optimizing the use of cyclosporine (Neoral) for recipients of living donor kidneys.
Transplant Proc. 2004 Mar;36(2 Suppl):50S-53S. doi: 10.1016/j.transproceed.2004.01.050.
6
Use of immunosuppressive agents in uveitis.
Curr Opin Ophthalmol. 2003 Dec;14(6):399-412. doi: 10.1097/00055735-200312000-00014.
8
Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation.
Kidney Int Suppl. 2002 Dec(82):S81-7. doi: 10.1046/j.1523-1755.62.s82.16.x.
10
Systemic cyclosporin A in high failure risk, repeated corneal transplantation.
Br J Ophthalmol. 2002 Sep;86(9):988-92. doi: 10.1136/bjo.86.9.988.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验